ESMO 2023

5 year follow-up

DATO-DX - where is it going?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

My highlights of ESMO23 in metastatic breast cancer

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Lu-PSMA leads forward

When the history of ADC is written: Redefining first-line standard of care in mUC!

Early use of enzalutamide in advanced prostate cancer

The FGFR story in bladder cancer at ESMO23

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Tarlatamab in SCLC

ALINA - immediate change of practice!

My highlights from ESMO 2023

New and better biomarkers are needed!

Anticipated updates and exciting new data for checkpointinhibitors

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

Our guidelines are correct

Negative EFS results from NeoTrip

Preoperative checkpointinihition in ER+ disease

Immunoncology in eBC - triple negative and more?

Detailed view of nodal-negative patients

Ribociclib effective in all subtypes

MonarchE - trial update

HR+ study with > 20 % PCR

Clinically relevant effect of pembro also in PCR

My highlights of ESMO23 in early breast cancer

Highlights in eBC

New data on neoadjuvant immunotherapy

Analysis of tumour microenvironment and immunophenotype in TNBC

Pembrolizumab solidifies as SOC in early-stage TNBC

5 year follow-up

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Neoadjuvant IO - is their new strategy in HR+ breast cancer

ER-low corresponds diagnostically to ER-0 breast cancer

Consolidation of data in early HR+ and triple-negative breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Carry-over effects in monarchE confirmed

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

What was the most exciting news at ESMO23?

New ADC for metastatic breast cancer?

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

My highlights of ESMO23 in metastatic breast cancer

Improved oncological therapy with the smartphone

T-DXd in HER2+ patients with brain metastases

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

T-DXd - new standard of care for brain mets?

Benefit for SG even after intensive pretreatment

New ADC in HR+ disease

Abemaciclib remains consistent in 5-year follow-up

Even more new generation ADCs in breast cancer?

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd also effective for brain metastases

Duvalumab + Dato-DXd effective

TULIP: Trastuzumab duocarmazine without OS benefit

Patient-centered molecular medicine - a new approach

Robust data from the monarchE

Can surgery be spared following primary systemic therapy?

HER2DX in the PHERgain trial

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Our guidelines are correct

Highlights in mBC

Dato-DXd - new player in advanced luminal disease

OP seems to be dispensable for super responders

Still on track for success in HER2-low MBC

HS20089 - a novel ADC is coming for TNBC

Fulvestran better than anastrozole, but no survival benefit

ADC + Immunotherapy - the BEGONIA study paradigm

DATO-DX - where is it going?

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

HER2DX en el estudio PHERgain

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Punti salienti in mBC

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Lo studio BEGONIA nelle paziento con tumore triplo negativo

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Should we use zoledronic acid in all ADT patients?

Combination of radioligand therapy with chemotherapy useful

Negative data for pembrolizumab in mHSCPC & mCRPC

Precision medicine at mCRCP

Embark without fear

PSMA FORE: Trial and controversies

EMBARK expands ENZA indication to PCa

Early use of enzalutamide in advanced prostate cancer

TITAN: ultra-low PSA = best prognosis

Brave New World in mCRPC

ENZA P:Trial and controversies

Salvage radiotherapy the new standard

Longterm toxicity of adjuvant RT after prostatectomy

IO therapy in metastatic prostate cancer.

Osteoprotection at mHSPC

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

CXCR2 inhibitor in PCa

EMBARK - Quality of Life

RADICALS RT: Trial and controversies

Big data and AI prediction tools

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Lu-PSMA leads forward

PSMAfore unleashes urooncologic opportunity

Immunotherapy in metastatic PCa

Immunterapi vid prostatacancer

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

CXCR2 hämmare och prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Unique bladder delivery system of gemcitabine herolds remarkable response

When the history of ADC is written: Redefining first-line standard of care in mUC!

New SoC in firstline bladder cancer

The FGFR story in bladder cancer at ESMO23

Amazing new data in bladder cancer

DAD, DAD-IO

EV + Pembro as standard of care in first-line therapy of bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Where does the future therapy go in renal cell carcinoma?

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

New 3rd line therapy for RCC

Intermittent therapy also possible with TKIs

New mode of action in mRCC - ready for prime time?

Clearing up non-clear cell RCC

Belzutifan - whats next kidney cancer?

Kidney cancer highlights at ESMO23

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Substantial improvement in local regional NSCLC

Big improvements in early stage and a subset of metatstic NSCLC

ALINA - immediate change of practice!

My highlights from ESMO 2023

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Circulating DNA in AEGEAN trial

Perioperative IO: OS-benefi from KEYNOTE-671

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Scene is set for inductive immunotherapy

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Evolving landscape of ADCs

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

By unanimous decision and still the champion – docetaxel!

Practice changing results on exon 20 insertion mNSCLC

LIBRETO - a positive study, but was it necessary?

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

PAPILLON - bringing together therapy for the 1st line

Substantial improvement in rare alterations

Do ADCs have brain activity?

Brain metastases – options to improve the systemic treatment

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Changing treatment landscape in EGFR-mutated NSCLC

MARIPOSA: Trial and controversies

Does immunotherapy still have a place in EGFR-positive mNSCLC?

MARIPOSA II: Trial and controversies

NRG fusions: a new drugable target?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

My highlights from ESMO 2023

TROPION-Lung01: positive development

Big improvements in early stage and a subset of metatstic NSCLC

Amivantamab upfront? MARIPOSA trial

Treatment sequences for EGFR-mutated Patients

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Amivantamab at progression? MARIPOSA-2 trial

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Amivantamab upfront? MARIPOSA trial

Quelles séquences thérapeutiques pour les patients EGFR mutés

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab at progression? MARIPOSA-2 trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Impact of T-cell engagers in SCLC

New hope for patients with SCLC

A new option in relapsed SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Update on gynaecological cancers

First data on luveltamab in multiline treatment for endometrial cancer

PCO Therapeutics

Precision oncology in CUP

New data on H&N Cancer

New data on sarkomas

Evolution of the revolution - the RUBY trial